Sodexo Unveils Shift & Grow 2030 Strategy, Targets Over 5% Revenue Growth by Fiscal 2030 
Richemont Q1 Sales Beat Forecast as Cartier Demand Drives Strong Growth 
Hyundai Takes Full Control of Boston Dynamics to Accelerate Humanoid Robot and AI Strategy 
xAI Sues Man for Allegedly Using Grok to Generate AI Child Abuse Deepfakes 
NY Times Challenges Trump Administration Subpoenas Over Air Force One Report 
UBS Boosts China Tech Bets, Adds Kuaishou and Meituan to Focus List 
SK Hynix Stock Soars as AI Memory Demand Outlook Fuels Chip Rally 
Taiwan Mangoes Head to Europe as Premium Fruit Exports Expand 
DBS Targets S$1 Trillion Wealth AUM by 2030 Amid Asia Wealth Boom 
Apple Intelligence China Approval Lifts Alibaba and Baidu Shares 
DeepSeek Eyes China IPO as AI Startup Seeks $71 Billion Valuation in New Funding Round 
Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside 
ASML Raises 2026 Outlook as AI Chip Demand Lifts Q2 Earnings 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
United Airlines Beats Q2 Earnings, Raises 2026 Profit Outlook Despite Higher Fuel Costs 
SpaceX Stock Falls Below IPO Price as Investors Weigh Losses and Lockup Expiry 
BHP Faces Major Port Hedland Strike as Labor Talks Stall Ahead of Production Report 
TEL AVIV, Israel, Jan. 28, 2016 -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced upcoming corporate presentations at the BIO CEO and Investor Conference and the 1st Annual Neuroscience BioPartnering & Investment Forum.
| BIO CEO & Investor Conference | |
| Date: | Monday, February 8 |
| Time: | 8:30am ET |
| Location: | Waldorf Astoria, New York, NY |
| 1st Annual Neuroscience BioPartnering & Investment Forum | |
| Date: | Tuesday, February 23 |
| Time: | 4:10pm ET |
| Location: | The New York Academy of Sciences, New York, NY |
About Alcobra Ltd.
Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX, to treat cognitive disorders including ADHD and FXS. For more information please visit the Company's website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.
U.S. Investor Contacts LifeSci Advisors, LLC Michael Rice 646-597-6979 [email protected] Media Inquiries Sam Brown, Inc. Mike Beyer 773-463-4211 [email protected] Israel Investor Contact: Alcobra Investor Relations Debbie Kaye +972-72 2204661 [email protected]
